Health · Pharma & Biotech · 11 hrs ago
FDA rejects Capricor’s Duchenne therapy for a second time
The FDA rejected Capricor Therapeutics’ deramiocel for a second time on Friday.
The cell therapy was developed for people with Duchenne muscular dystrophy, a progressive disease that weakens muscles.
Capricor had narrowed the group of patients it sought approval to treat, but the FDA still cited significant issues with the trial.
The intended patients were teenagers and young men who had already lost the ability to walk and have few treatment options.
In two randomized trials, deramiocel did not show it could prevent heart failure or preserve arm muscle function.
The rejection means the therapy cannot reach the market for these patients, and no further steps were specified.
The FDA rejected Capricor Therapeutics’ deramiocel cell therapy for Duchenne muscular dystrophy on Friday.
It was the therapy’s second rejection, according to Endpoints News.
The FDA cited significant issues with a trial, Endpoints News reported.
STAT reported that two randomized trials failed to show the therapy could prevent heart failure or preserve arm muscle function.
The intended patients included teenagers and young men with Duchenne who had lost the ability to walk.
- Who
- The FDA rejected the therapy developed by Capricor Therapeutics.
- What
- It rejected deramiocel, a cell therapy intended for people with Duchenne muscular dystrophy.
- When
- Friday, Nov. 20, 2026.
- Where
- Not stated.
- Why
- STAT reported that two randomized trials failed to show the therapy could prevent heart failure or preserve arm muscle function. Endpoints News said the FDA cited significant issues with a trial.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Drug
- Deramiocel, a cell therapy
- Developer
- Capricor Therapeutics
- Decision
- FDA rejected the therapy on Friday, Nov. 20, 2026
- Trial results
- Two randomized trials failed to show benefit in preventing heart failure or preserving arm muscle function
- Intended patients
- Teenagers and young men with Duchenne who had lost the ability to walk